Tharimmune, Inc.

THAR

US4327052001

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 03:42:24 2024-05-15 pm EDT			5-day change	1st Jan Change
0.365 ^USD	+0.11%		-11.18%	-28.55%

May. 09	Tharimmune, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 23	Tharimmune, Inc. Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates	CI

Tharimmune, Inc. has Changed its Ticker to THAR from HILS

September 25, 2023 at 12:00 am EDT

Effective September 25, 2023, Tharimmune, Inc. changed its Nasdaq Capital Market stock ticker symbol to THAR from HILS.

Latest news about Tharimmune, Inc.

Tharimmune, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
Tharimmune, Inc. Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates	Apr. 23	CI
Tharimmune, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 23	CI
Tharimmune, Inc. Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic Candidate	Feb. 20	CI
Tharimmune, Inc. Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitis	Feb. 05	CI
Tharimmune, Inc. Announces Initiation of Phase 1 Clinical Trial of TH104	Jan. 29	CI
Tharimmune Sees 'Positive' Data With TH104 for Pruritus in Chronic Liver Disease	Dec. 11	MT
Tharimmune, Inc. Announces Positive Topline Data with Th104, Its Lead Candidate for Moderate-To-Severe Pruritus in Chronic Liver Disease Patients	Dec. 11	CI
Sector Update: Health Care Stocks Retreat in Late Afternoon	Nov. 28	MT
Top Midday Decliners	Nov. 28	MT
Traders Await Economic Data as US Equity Futures Post Narrow Losses Pre-Bell	Nov. 28	MT
Top Premarket Decliners	Nov. 28	MT
Tharimmune Prices $10 Million Public Share Offering	Nov. 28	MT
Tharimmune Reports Positive Phase 1 Data on Th104, Its Lead Therapeutic Candidate, for Chronic Pruritis in Primary Biliary Cholangitis	Nov. 27	CI
Sector Update: Health Care Stocks Slipping Late Afternoon	Nov. 17	MT
Sector Update: Health Care Stocks Softer Friday Afternoon	Nov. 17	MT
Tharimmune to Implement 1-for-25 Reverse Stock Split	Nov. 17	MT
Tharimmune, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Tharimmune, Inc. Announces Execution of an Exclusive Worldwide Licensing Agreement with Avior Inc. D/B/A Avior Bio, Llc ("Avior") to Develop, Market and Commercialize A Clinical-Stage Asset, Av104 (To Be Renamed Th104 and Hereinafter Referred to as Th104)	Nov. 06	CI
Certain Warrants of Hillstream BioPharma, Inc. are subject to a Lock-Up Agreement Ending on 24-OCT-2023.	23-10-23	CI
Certain Options of Hillstream BioPharma, Inc. are subject to a Lock-Up Agreement Ending on 24-OCT-2023.	23-10-23	CI
Certain Common Stock of Tharimmune, Inc. are subject to a Lock-Up Agreement Ending on 24-OCT-2023.	23-10-23	CI
Tharimmune, Inc.(NasdaqCM:THAR) added to NASDAQ Composite Index	23-09-25	CI
Tharimmune, Inc. has Changed its Ticker to THAR from HILS	23-09-25	CI
Hillstream BioPharma Inc. has Changed its Name to Tharimmune, Inc	23-09-25	CI

Tharimmune, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of therapeutic candidate for inflammatory and immunologic conditions. It has a transmucosal film product, TH104 in Phase I clinical development, two bispecific candidates and a Picobody candidate in pre-clinical development. TH104 is a transmucosal buccal film embedded with the active compound nalmefene onto a thin film which adheres inside of the mouth on the cheek and biodegrades. TH104 is an ideal product candidate for multiple liver-related and other pruritogenic inflammatory conditions. It is also developing an early-stage pipeline of novel therapeutic candidates targeting validated high value immune-oncology (IO) targets including human epidermal growth factor (EGF) receptor 2 (HER2), human EGF receptor 3 (HER3) and programmed cell death protein (PD-1). The Company is developing antibodies, including bispecific antibodies, antibody drug conjugates (ADCs) and others.

Sector

Biotechnology & Medical Research

Calendar

2024-05-14 - EF Hutton Investor Conference

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.3646 USD

Average target price

5 USD

Spread / Average Target

+1,271.37%

Consensus

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
THARIMMUNE, INC.	-28.55%	4.3M
VERTEX PHARMACEUTICALS INCORPORATED	+7.44%	111B
REGENERON PHARMACEUTICALS, INC.	+11.30%	106B
BIONTECH SE	-12.70%	22.24B
ARGENX SE	+0.44%	21.25B
GENMAB A/S	-4.18%	18.97B
WUXI APPTEC CO., LTD.	-37.85%	18.52B
BEIGENE, LTD.	-8.76%	16.81B
SAREPTA THERAPEUTICS, INC.	+37.44%	12.54B
LEGEND BIOTECH CORPORATION	-24.00%	8.09B

Bio Therapeutic Drugs

Tharimmune, Inc.

Equities

THAR

US4327052001

Biotechnology & Medical Research

Tharimmune, Inc. has Changed its Ticker to THAR from HILS

Latest news about Tharimmune, Inc.

Chart Tharimmune, Inc.

Company Profile

Income Statement Evolution

Analysts' Consensus

Annual profits - Rate of surprise

Sector Bio Therapeutic Drugs